SRFP1 Antibody

What is SFRP1 and why is it important in molecular research?

SFRP1 (Secreted Frizzled-Related Protein 1) is a secreted glycoprotein that functions as a Wnt signaling antagonist. It contains a cysteine-rich domain homologous to the putative Wnt-binding site of Frizzled proteins. SFRP1 is critically important in research because:

• It modulates the Wnt signaling pathway through direct interaction with Wnts

• It plays significant roles in cell growth regulation and differentiation

• SFRP1 is highly expressed in kidney and has demonstrated protective functions against renal damage

• It acts as a tumor suppressor, with epigenetic silencing associated with cancer development

• SFRP1 is involved in cellular senescence mechanisms

SFRP1 protein is typically observed at 30-35 kDa by Western blotting, though its calculated molecular weight is approximately 35.4 kDa .

What tissues express SFRP1 and how does expression vary in disease states?

SFRP1 shows distinct tissue expression patterns that researchers should consider when designing experiments:

Disease-specific expression changes:

• Renal damage: SFRP1 protein is markedly increased after unilateral ureteral obstruction (UUO)

• Emphysema: SFRP1 is induced in the lungs of patients with emphysema

• Cancer: Often silenced through epigenetic mechanisms

What applications are SFRP1 antibodies validated for and what are the recommended dilutions?

SFRP1 antibodies have been validated for multiple applications with specific dilution recommendations:

It is critical to optimize antibody concentrations for each experimental system. For example, the Proteintech antibody (26460-1-AP) has been validated for WB at dilutions between 1:2000-1:12000, while their 28271-1-AP antibody is recommended at 1:500-1:1000 for the same application .

How should I validate SFRP1 antibody specificity for my research?

Proper validation of SFRP1 antibodies is essential for reliable results. Research indicates the following methodological approach:

• Knockout/knockdown controls: Use SFRP1 knockout cell lines or siRNA-mediated knockdown samples as negative controls

  • A recent study characterized 11 commercial SFRP1 antibodies using knockout cell lines and isogenic parental controls

• Recombinant protein testing: Verify antibody specificity against recombinant SFRP1 protein

  • Western blotting with recombinant SFRP proteins (mouse Sfrp1-5) demonstrated that a well-characterized monoclonal antibody reacted only with Sfrp1, not with other Sfrp family members

• Multiple detection methods: Confirm findings using different techniques (WB, IHC, IF)

• Expected molecular weight verification: SFRP1 should appear at approximately 30-35 kDa on Western blots

• Positive control tissues: Use tissues known to express SFRP1 (e.g., testis, kidney)

  • Human testis tissue has been validated as a positive control for WB detection

What are the critical experimental controls when working with SFRP1 antibodies?

Proper controls are essential for SFRP1 research integrity:

Research demonstrates the importance of these controls: "In the wild-type UUO-operated kidneys, fibrotic lesion in the cortex was observed after the surgery... In contrast, the development of tubulointerstitial injury was progressively deteriorated in the homozygous UUO kidney" .

How does SFRP1 function in the Wnt signaling pathway and what methodologies best detect this activity?

SFRP1 functions as a Wnt antagonist through multiple mechanisms:

• Direct Wnt binding: SFRP1 can sequester Wnt ligands, preventing their interaction with Frizzled receptors

  • Detection method: Co-immunoprecipitation of SFRP1 with Wnt proteins

• Canonical pathway inhibition: SFRP1 decreases intracellular β-catenin levels

  • Detection method: TOPFlash/FOPFlash reporter assays to measure TCF/LEF-dependent transcription

• Non-canonical pathway modulation: In kidney, SFRP1 inhibits renal damage through the non-canonical Wnt/PCP pathway

  • Detection method: Measure phosphorylation of c-Jun and JNK, which were "significantly elevated in the obstructed Sfrp1−/− kidneys"

Research findings demonstrate: "These results indicate that Sfrp1 is required for inhibition of renal damage through the non-canonical Wnt/PCP pathway" . Interestingly, "The activity of β-catenin did not alter in the obstructed kidney," suggesting tissue-specific pathway utilization .

What role does SFRP1 play in cellular senescence and how can this be experimentally evaluated?

SFRP1 has emerged as a critical mediator of cellular senescence:

• Senescence induction: SFRP1 is oversecreted upon cellular senescence caused by DNA damage or oxidative stress

• Functional necessity: "SFRP1 is necessary for stress-induced senescence caused by these factors and is sufficient for the induction of senescence phenotypes"

• Mechanism: SFRP1 appears to induce senescence through inhibition of Wnt signaling and activation of the retinoblastoma (Rb) pathway

Experimental methods to evaluate SFRP1 in senescence:

• Senescence-associated β-galactosidase (SA-β-gal) assays

• Detection of senescence-associated heterochromatic foci (SAHF)

• Antibody blocking experiments using neutralizing SFRP1 antibodies

• Co-culture experiments with SFRP1-expressing cells and GFP-labeled young cells

Methodology example: "For antibody blocking experiments, cells were treated with 1 μg/ml of neutralizing antibodies or IgG 24 h after etoposide treatment or SFRP1 viral infection" .

How can I differentiate between intracellular and secreted forms of SFRP1 in my experiments?

SFRP1 exists in both intracellular and secreted forms, requiring specialized techniques to differentiate between them:

• Cell lysate vs. conditioned media analysis:

  • Cell lysate: Detects intracellular SFRP1

  • Conditioned media: Detects secreted SFRP1

• Brefeldin A treatment: "SFRP1 protein abundance in the whole-cell lysate of IMR-90 cells treated with brefeldin A, an inhibitor of protein transport from endoplasmic reticulum (ER) to the Golgi compartment, displayed pronounced increase upon etoposide treatment"

• Heparin treatment: "A previous study demonstrated that a significant fraction of secreted SFRP1 is attached to the cell surface and can be efficiently released to the culture medium by heparin treatment"

  • "Heparin increases the levels of free extracellular SFRP1"

• Cell surface vs. matrix association: SFRP1 can be "cell membrane or extracellular matrix-associated" and "released by heparin-binding"

• Immunofluorescence localization: In human kidney, "specific staining was localized to epithelial cell cytoplasm in convoluted tubules"

How should I interpret contradictory results from different SFRP1 antibodies?

When faced with contradictory results from different SFRP1 antibodies, consider these methodological approaches:

• Antibody validation status: A recent study "characterized 11 sFRP-1 commercial antibodies for Western Blot and immunoprecipitation, using a standardized experimental protocol"

  • Check if your antibodies were included in this validation study

• Epitope differences: Different antibodies target different regions of SFRP1

  • N-terminal antibodies (e.g., AP9037a) target amino acids 26-55

  • Other antibodies target the full protein (Ser32-Lys314)

  • Epitope location may affect detection in different contexts

• Cross-reactivity assessment: Test for reactivity with other SFRP family members

  • "Western blotting was performed using recombinant Sfrp proteins (mouse Sfrp1–5). This antibody was only reacted with Sfrp1, but not with other Sfrp proteins"

• Species-specific validation: Confirm reactivity with your species of interest

  • Some antibodies are human-specific (28271-1-AP)

  • Others react with human and mouse (26460-1-AP)

• Functional validation: Use biological assays to confirm antibody functionality

  • Neutralizing capacity in cellular assays

  • Ability to detect phenotypic changes in knockout models

What factors affect the detection of SFRP1 in different experimental systems?

Several factors can influence SFRP1 detection:

• Protein processing and modifications:

  • Glycosylation may affect antibody recognition

  • Proteolytic processing can generate fragments

• Expression level variability:

  • "Sfrp1 protein was increased at different time points in the obstructed kidneys"

  • Baseline expression varies significantly between tissues

• Cell-surface binding:

  • "A significant fraction of secreted SFRP1 is attached to the cell surface"

  • Heparin treatment can release this fraction

• Functional redundancy:

  • "To examine the extent of functional redundancy between three Sfrp members, we investigated Sfrp1−/− UUO kidneys with graded levels of Sfrp2 and Sfrp5 protein expressions"

  • "Deletion of Sfrp1 did not result in a compensatory increase of the remaining gene product, Sfrp2 and Sfrp5 proteins"

• Sample preparation:

  • For immunohistochemistry: "suggested antigen retrieval with TE buffer pH 9.0; alternatively, antigen retrieval may be performed with citrate buffer pH 6.0"

  • For Western blot: Protein extraction method affects detection efficiency

How can I optimize SFRP1 antibody performance for challenging applications?

For challenging applications, consider these optimization strategies:

• Western blot optimization:

  • Titrate antibody concentration (1:500-1:12000 range reported)

  • Try different blocking agents (BSA vs. milk)

  • Consider native vs. denaturing conditions

• Immunohistochemistry enhancement:

  • Buffer optimization: "suggested antigen retrieval with TE buffer pH 9.0; alternatively, antigen retrieval may be performed with citrate buffer pH 6.0"

  • Signal amplification systems: "Tissue was stained using the Anti-Goat HRP-DAB Cell & Tissue Staining Kit"

  • Incubation conditions: "1 µg/mL overnight at 4°C"

• Immunofluorescence refinement:

  • Cell fixation method: "SFRP1 was detected in immersion fixed MBA-MB-468 human breast cancer cell line"

  • Antibody concentration: "15 µg/mL for 3 hours at room temperature"

  • Visualization: "NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody"

• Increasing detection sensitivity:

  • For cell-surface SFRP1: "Heparin increases the levels of free extracellular SFRP1"

  • For intracellular detection: "Brefeldin A, an inhibitor of protein transport from endoplasmic reticulum (ER) to the Golgi compartment, displayed pronounced increase"

• Storage and handling:

  • "Store at -20°C. Stable for one year after shipment."

  • "Aliquoting is unnecessary for -20°C storage."

How is SFRP1 involved in tissue repair and regeneration?

SFRP1 plays complex roles in tissue repair and regeneration:

• Cardiac repair: "Through genetic and pharmacological modification of Sfrp1 gene, the efficacy could be potentially augmented in the treatment of ischemic heart disease"

  • "When Sfrp1 gene was knocked down, the MI-pSC-induced cardiac benefits were substantially hampered, suggesting the obligatory role of Sfrp1 that mediated the MI-pSC-induced cardiac structural repair and functional improvement"

• Renal protection: "Sfrp1 is required for inhibition of renal damage through the non-canonical Wnt/PCP pathway"

  • Loss of Sfrp1 in knockout mice leads to "increased renal fibrosis during unilateral ureteral obstruction"

• Dual role in lung disease: "SFRP1 promotes normal alveolar formation in lung development, although its expression in the adult up-regulates proteins that can cause tissue destruction"

  • "SFRP1 induction during tissue injury is unlikely to contribute to the repair response but rather is a participatory factor in the pathogenesis of emphysema and tissue destruction"

• MMP regulation: "Treatment with purified SFRP1 increased MMP1 and MMP9 protein levels in SAE cell media but did not affect TIMP1 (the natural inhibitor) protein levels"

  • "The treatment of SAE cells with SFRP1 activated ERK1/2, which is known to regulate MMP expression"

What novel methodologies are emerging for studying SFRP1 function?

Cutting-edge methodologies for SFRP1 research include:

• Standardized antibody validation:

  • "A standardized experimental protocol based on comparing read-outs in knockout cell lines and isogenic parental controls"

  • Part of "a larger, collaborative initiative seeking to address the antibody reproducibility issue by characterizing commercially available antibodies"

• Genetic manipulation in model systems:

  • SFRP1 knockout mice for phenotypic analysis

  • siRNA-based knockdown: "Targeted suppression of Sfrp1 gene diminished the number of positive cells and significantly reduced the secretion of Sfrp1 protein in culture medium"

• Pathway dissection approaches:

  • Distinction between canonical and non-canonical Wnt signaling effects

  • "The activity of β-catenin did not alter in the obstructed kidney" despite SFRP1 effects

• Cell-based functional assays:

  • Senescence assays: "Senescence-associated beta-galactosidase assays and detection of senescence-associated heterochromatic foci (SAHF)"

  • Co-culture systems: "GFP-labeled young cells were cocultured with etoposide-treated cells, SFRP1-expressing cells, or control cells"

• Therapeutic applications:

  • "Stem cell-based therapy is indeed a cardiac protective intervention and, through genetic and pharmacological modification of Sfrp1 gene, the efficacy could be potentially augmented"